The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Neurohumoral Prediction of Benefit From Carvedilol in Ischemic Left Ventricular Dysfunction
Open accessAbstract
Background —Plasma neurohormones were analyzed for prediction of adverse outcomes and response to treatment in 415 patients with ischemic left ventricular dysfunction randomly assigned to receive carvedilol or placebo. Methods and Results —Atrial natriuretic peptide, brain natriuretic peptide (BNP), or norepinephrine (NE) levels above the group median were associated with increased mortality rates and heart failure. On multivariate analysis, both BNP and NE interacted with treatment to predict death or heart failure independent of age, New York Heart Association class, and left ventricular ejection fraction. For placebo, supramedian levels of BNP were associated with 3-fold the mortality rate of inframedian levels (20/104; 19% vs 6/99; 6%; P <0.01). For carvedilol, mortality rate was comparable in these 2 subgroups (12/109; 11% vs 8/94; 9%; NS). Corresponding rates for heart failure were 29/104 (28%) versus 3/99 (3%; P <0.001) for placebo and 16/109 (15%) versus 7/94 (7%; NS) for carvedilol. High NE levels did not predict additional benefit from carvedilol, which significantly reduced heart failure admissions only in those with NE levels below the median (13.1% to 4.0%; P <0.01). In the 23% of the study population with supramedian BNP but inframedian levels of NE, carvedilol reduced hospital admission with heart failure by >90% ( P <0.001). Conclusions —Carvedilol reduced mortality rates and heart failure in those with higher pretreatment BNP levels but lesser activation of plasma NE. Neurohumoral profiling may guide introduction of β-blockade in heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure
Cohn, J. N., Levine, T. B., Olivari, M. T., Garberg, V., Lura, D., Francis, G. S., Simon, A. B., & Rector, T. (1984) · New England Journal of Medicine · doi:10.1056/nejm198409273111303 · Cited by 3,125
Vantrimpont, P., Rouleau, J. L., Wun, C.-C., Ciampi, A., Klein, M., Sussex, B., Arnold, J. M. O., Moyé, L., & Pfeffer, M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00489-5 · Cited by 274
Cited by
B-type natriuretic peptide in cardiovascular disease
de Lemos, J. A., McGuire, D. K., & Drazner, M. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13976-1 · Cited by 1,067
State of the art: using natriuretic peptide levels in clinical practice
Maisel, A., Mueller, C., Adams, K., Anker, S. D., Aspromonte, N., Cleland, J. G. F., Cohen-Solal, A., Dahlstrom, U., DeMaria, A., Di Somma, S., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.07.014 · Cited by 839
B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure
Berger, R., Huelsman, M., Strecker, K., Bojic, A., Moser, P., Stanek, B., & Pacher, R. (2002) · Circulation · doi:10.1161/01.cir.0000016642.15031.34 · Cited by 706
Cheng, V., Kazanagra, R., Garcia, A., Lenert, L., Krishnaswamy, P., Gardetto, N., Clopton, P., & Maisel, A. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01157-8 · Cited by 668
Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure
Jourdain, P., Jondeau, G., Funck, F., Gueffet, P., Le Helloco, A., Donal, E., Aupetit, J. F., Aumont, M. C., Galinier, M., Eicher, J. C., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.081 · Cited by 646
Metadata
- Authors
- Richards, A. M., Doughty, R., Nicholls, M. G., Macmahon, S., Ikram, H., Sharpe, N., Espiner, E. A., Frampton, C., & Yandle, T. G.
- Venue
- Circulation
- Published
- 1999-02-16
- Volume
- 99
- Issue
- 6
- Pages
- 786-792
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2058209034
- Cited by
- 212
- References
- 2
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurohumoral Prediction of Benefit From Carvedilol in Ischemic Left Ventricular Dysfunction. https://app.cochat.ai/papers/10.1161/01.cir.99.6.786
- The paper
- Richards, A. M., Doughty, R., Nicholls, M. G., Macmahon, S., Ikram, H., Sharpe, N., Espiner, E. A., Frampton, C., & Yandle, T. G. (1999). Neurohumoral Prediction of Benefit From Carvedilol in Ischemic Left Ventricular Dysfunction. Circulation. https://doi.org/10.1161/01.cir.99.6.786
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.